Drug intelligence / Profile preview

mercaptopurine + prednisolone + vincristine

Development stage: Unknown
Lead developer: National Cancer Institute
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination chemotherapy regimen consisting of mercaptopurine, prednisolone, and vincristine. While this specific three-drug combination is not explicitly described in the search results as a standalone regimen, it constitutes a significant part of the commonly known POMP regimen for acute lymphoblastic leukemia (ALL). The full POMP regimen typically includes methotrexate in addition to these three drugs, and is often used as maintenance therapy in ALL treatment protocols.

Targets

GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)

Beyond the preview

Go deeper on mercaptopurine + prednisolone + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mercaptopurine + prednisolone + vincristine.

Explore the full profile